Production (Stage)
Inhibrx Biosciences, Inc.
INBX
$14.39
$0.473.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -88.78% | -88.89% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.78% | -88.89% | -- | -- | -- |
| Cost of Revenue | -10.92% | -24.82% | -- | -- | -- |
| Gross Profit | 10.03% | 24.21% | -- | -- | -- |
| SG&A Expenses | 69.78% | 103.93% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.32% | 19.28% | -- | -- | -- |
| Operating Income | 6.73% | -20.17% | -- | -- | -- |
| Income Before Tax | 735.43% | 799.20% | -- | -- | -- |
| Income Tax Expenses | -33.33% | -33.33% | -- | -- | -- |
| Earnings from Continuing Operations | 735.42% | 799.19% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 735.42% | 799.19% | -- | -- | -- |
| EBIT | 6.73% | -20.17% | -- | -- | -- |
| EBITDA | 7.31% | -19.77% | -- | -- | -- |
| EPS Basic | 653.23% | 673.67% | -- | -- | -- |
| Normalized Basic EPS | 27.48% | 8.09% | -- | -- | -- |
| EPS Diluted | 645.65% | 665.61% | -- | -- | -- |
| Normalized Diluted EPS | 28.15% | 8.80% | -- | -- | -- |
| Average Basic Shares Outstanding | 22.37% | 25.62% | -- | -- | -- |
| Average Diluted Shares Outstanding | 22.75% | 26.02% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |